Uro-oncology · KIMS Secunderabad
Upper Tract Urothelial Carcinoma (UTUC) — Cancer of the Kidney Pelvis and Ureter
Upper tract urothelial carcinoma (UTUC) is cancer arising from the urothelium — the specialised lining tissue that covers the renal pelvis (the collecting space within the kidney) and the ureter (the tube that carries urine from the kidney to the bladder). UTUC accounts for approximately 5 to 10% of all urothelial cancers — far less common than bladder cancer, which arises from the same cell type but in a much more accessible location. This relative rarity means UTUC is frequently diagnosed late, often presenting with haematuria that is investigated with cystoscopy (which examines only the bladder) but not with CT urogram (which is required to visualise the upper tract).
UTUC is a potentially curable cancer when detected at the localised stage — and the treatment of choice is robotic radical nephroureterectomy (RNU), removal of the kidney, entire ureter, and bladder cuff, performed at KIMS using the Da Vinci Xi or X. At KIMS, every case of UTUC is reviewed at the multidisciplinary tumour board before treatment is planned, and every decision between radical treatment, kidney-sparing endoscopic management, and systemic therapy is made by the full team.
Who is at risk for UTUC
UTUC predominantly affects older smokers, but several other risk factors substantially raise the lifetime probability of upper tract cancer — including hereditary syndromes that warrant family genetic counselling.
Smoking — the most important modifiable risk factor
Carcinogenic compounds in tobacco are excreted in the urine and concentrate in the upper tract, causing urothelial damage. Smoking cessation is the single most important modifiable risk-reduction intervention.
Age above 60
Peak incidence is in the seventh decade. Rare before age 40. UTUC under age 60 should always prompt consideration of an underlying hereditary syndrome (Lynch syndrome) or aristolochic acid exposure.
Prior bladder cancer
Patients with bladder cancer have a 2 to 4% risk of developing UTUC. Patients with UTUC have a 15 to 50% lifetime risk of developing bladder cancer — the entire urothelium (from kidneys to bladder) shares the same carcinogenic exposure and genetic susceptibility.
Aristolochic acid nephropathy
Chinese herbal medicine containing aristolochic acid (from Aristolochia species) causes a specific nephropathy and dramatically elevated UTUC risk (up to 40% lifetime risk in heavily exposed patients). This is particularly relevant in Taiwan and parts of Southeast Asia where these herbs were historically used.
Lynch syndrome (HNPCC) — hereditary risk
MMR gene mutations (MLH1, MSH2, MSH6, PMS2) dramatically increase the lifetime risk of UTUC (up to 20 to 25% in MSH2 carriers). UTUC in a patient under 60, or with a family history of colorectal, endometrial, or other Lynch-associated cancers, warrants genetic testing.
Analgesic nephropathy
Chronic use of phenacetin-containing analgesics is associated with renal pelvis carcinoma. Now rare as phenacetin has been withdrawn from the market.
Symptoms — painless haematuria is the cardinal sign
Painless haematuria — the most common presenting symptom. Visible blood in the urine without pain, as with bladder cancer, is the classic presentation. UTUC haematuria may be intermittent — disappearing for weeks before recurring.
Loin pain — from obstruction of the ureter by the tumour, causing hydronephrosis. The pain is typically dull and constant (from progressive hydronephrosis) rather than colicky (which suggests a mobile stone).
A flank mass — from the obstructed, hydronephrotic kidney. Less common as a presenting feature since most UTUC is now detected by CT.
Ureteric colic — passage of a blood clot from the tumour through the ureter can cause acute renal colic pain indistinguishable from stone colic. CT KUB shows no stone but may show ureteric filling defect.
Incidental detection — UTUC is increasingly found incidentally on CT performed for other reasons.
Any episode of visible haematuria in an adult — particularly above 40 — requires CT urogram as part of the investigation, not just flexible cystoscopy. Cystoscopy examines the bladder but cannot visualise the renal pelvis or ureter. A normal cystoscopy does not exclude UTUC. CT urogram with full excretory phase imaging is the investigation that detects upper tract filling defects caused by UTUC.
Diagnosis at KIMS
CT urogram
The most sensitive investigation for UTUC. Performed in three phases — non-contrast (for stones), nephrographic (for parenchymal lesions), and excretory (for the filled upper tract — where UTUC appears as a filling defect or mass within the renal pelvis or ureter). CT also provides staging information — lymph node involvement, local invasion, and distant metastases.
Urine cytology
Examination of shed urothelial cells in the urine for malignant features. Sensitivity for UTUC is lower than for bladder cancer — approximately 40 to 50% for high-grade UTUC and much lower for low-grade tumours. A positive urine cytology in the context of a normal cystoscopy and upper tract filling defect strongly suggests UTUC.
Ureteroscopy with biopsy
Flexible ureteroscopy allows direct visual examination of the entire ureter and renal pelvis — the endoscope is passed retrogradely through the urethra, bladder, and into the ureter, reaching the renal pelvis. Suspicious lesions can be biopsied under direct vision. Ureteroscopy with biopsy is performed when CT findings are equivocal, or when tissue confirmation is required before proceeding to nephroureterectomy. Biopsy grade on ureteroscopic sample correlates with final pathological grade in approximately 70 to 80% of cases.
MRI urogram
An alternative to CT urogram when iodinated contrast is contraindicated (reduced eGFR, contrast allergy). MRI provides excellent soft tissue detail and can characterise upper tract masses well, though spatial resolution for small urothelial tumours is slightly lower than CT.
Staging and risk stratification
UTUC stage determines whether kidney-sparing endoscopic treatment, radical nephroureterectomy, or systemic chemotherapy is the right approach. The KIMS multidisciplinary tumour board reviews every case against the stage-by-stage framework below.
pTa — non-invasive papillary UTUC (rare in upper tract)
Excellent prognosis. Kidney-sparing endoscopic management (ureteroscopic laser ablation) may be considered for small, low-grade lesions in a solitary kidney or bilateral disease.
pT1 — invasion into the lamina propria
Good prognosis after radical surgery. RNU is standard for most T1 tumours.
pT2 — invasion into muscularis propria
Intermediate prognosis. RNU with perioperative cisplatin-based chemotherapy.
pT3 — invasion beyond muscularis into peripelvic/periureteric fat or renal parenchyma
Higher recurrence risk. RNU with neoadjuvant or adjuvant chemotherapy.
pT4 — invasion of adjacent organs or through renal cortex
Advanced local disease. RNU + chemotherapy ± radiation for selected cases.
N+ or M+ (lymph node or distant metastases)
Systemic cisplatin-based chemotherapy (gemcitabine + cisplatin) is the primary treatment. Immunotherapy (pembrolizumab, atezolizumab) for cisplatin-ineligible patients.
Robotic nephroureterectomy at KIMS
Radical nephroureterectomy (RNU) — removal of the kidney, the entire ureter from kidney to bladder, and a cuff of bladder at the ureteric orifice — is the standard treatment for most localised UTUC. At KIMS, robotic nephroureterectomy (RANU) is performed using the Da Vinci Xi — whose four-arm configuration enables both the kidney and pelvic dissections in the same operative sitting.
Radical nephroureterectomy — the standard treatment
Radical nephroureterectomy — removal of the kidney, the entire ureter from kidney to bladder, and a cuff of bladder at the ureteric orifice — is the standard treatment for most localised UTUC. The complete ureter must be removed (unlike partial ureterectomy for distal lesions) because the entire ureteral lining is at risk of recurrence. At KIMS, robotic nephroureterectomy (RANU) is performed using the Da Vinci Xi — whose four-arm configuration and multi-quadrant reach allows both the kidney dissection and the pelvic ureteral dissection and bladder cuff excision to be performed robotically without repositioning the patient or the robot.
KIMS advantage — Da Vinci Xi for RANU
The Xi's fourth arm provides independent tissue retraction during the pelvic dissection — holding the distal ureter under tension while the instruments dissect the bladder cuff. Centres with only the Da Vinci X (three arms) must rely on the assistant for pelvic retraction, which is less precise. The Xi's multi-quadrant capability allows the full procedure — from kidney to bladder — without robot or patient repositioning.
After nephroureterectomy for UTUC, lifelong surveillance cystoscopy is mandatory — the bladder is at risk for urothelial recurrence in 20 to 50% of UTUC patients within 2 years of surgery. Cystoscopy is performed every 3 months for year 1, 6-monthly for year 2, and annually thereafter. CT of the chest and abdomen is performed annually for upper tract recurrence and distant metastases in high-risk cases.
Book a UTUC Assessment at KIMS — Robotic Nephroureterectomy Available
Frequently Asked Questions — UTUC
Both UTUC and bladder cancer arise from the urothelium — the same specialised lining tissue that covers the entire urinary tract from the kidney to the bladder outlet. The distinction is location: bladder cancer arises in the bladder, while UTUC arises in the renal pelvis (the collecting space within the kidney) or the ureter. Because the urothelium is continuous, a patient who develops cancer in one location is at higher risk of developing it elsewhere — patients with UTUC have a 15 to 50% lifetime risk of developing bladder cancer; patients with bladder cancer have a 2 to 4% risk of developing UTUC. The treatment also differs: bladder cancer is usually treated with TUR-BT (endoscopic resection through the bladder); UTUC requires radical nephroureterectomy (removal of kidney and entire ureter) for most cases.
Kidney-sparing treatment — endoscopic ureteroscopic laser ablation of the tumour, without nephroureterectomy — is appropriate in specific circumstances: bilateral UTUC, UTUC in a solitary kidney (where nephroureterectomy would cause immediate dialysis dependence), low-grade low-stage tumour in a patient who cannot tolerate major surgery, or a small low-grade tumour accessible to complete endoscopic resection. However, kidney-sparing treatment carries a significantly higher local recurrence rate than radical nephroureterectomy for most UTUC — close surveillance with ureteroscopy every 3 to 6 months is required. The decision between radical and kidney-sparing treatment requires MDT review at KIMS.
Yes — early-stage UTUC (pTa and pT1, confined to the urothelium and lamina propria) has 5-year cancer-specific survival rates above 90% after radical nephroureterectomy. Stage pT2 (invasion into muscle) has 5-year survival of 60 to 70%. Stage pT3 (invasion into peripelvic fat or renal parenchyma) has 5-year survival of 40 to 50%. Metastatic UTUC (N+ or M+) has a much poorer prognosis — median survival of 12 to 18 months with chemotherapy. Early detection — before muscle invasion — is the critical determinant of outcome, which is why CT urogram must be performed for any episode of haematuria in an adult.
On CT urogram (particularly the excretory phase, performed 10 to 15 minutes after IV contrast injection when the upper tract is filled with contrast), UTUC appears as an irregular filling defect within the contrast-filled renal pelvis or ureter — a gap or irregularity in the column of white contrast that should uniformly fill the collecting system. Large tumours may appear as a soft tissue mass expanding or replacing the renal pelvis. Hydroureteronephrosis above the level of the tumour is a common finding when the tumour obstructs the ureter. The CT also evaluates for lymph node enlargement and distant metastases.
Yes — Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) is caused by mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2) and significantly increases the risk of urothelial cancer of the upper tract. MSH2 mutation carriers have a particularly high UTUC risk — approximately 20 to 25% lifetime risk. UTUC occurring before age 60, multifocal UTUC, or UTUC in a patient with a personal or family history of colorectal cancer, endometrial cancer, or other Lynch-associated cancers should prompt genetic counselling and testing. Identification of Lynch syndrome has implications for the entire family — cascade testing of first-degree relatives allows surveillance and early detection.
Both kidney stones and UTUC can cause haematuria and both can be detected on CT. The distinction: kidney stones appear as bright white, high-density calcifications on the non-contrast CT phase — they are almost impossible to miss on a properly performed non-contrast CT KUB. UTUC appears as a soft tissue mass or filling defect within the renal pelvis or ureter — it is visible primarily on the nephrographic and excretory phases of the contrast CT. A stone causes very bright hyperdense signal; UTUC causes a soft tissue density mass. In some cases, both coexist — a stone and a concurrent urothelial tumour — which is why haematuria in a patient with a stone still warrants excretory phase imaging to exclude an upper tract tumour.
Lifelong surveillance is required after radical nephroureterectomy for UTUC because of the 20 to 50% risk of bladder recurrence and the risk of contralateral upper tract recurrence in the remaining kidney. The KIMS surveillance protocol: cystoscopy every 3 months for year 1, every 6 months for year 2, annually from year 3. CT of the chest and abdomen every 6 months for years 1 and 2, annually from year 3 in high-risk cases. Urine cytology at each surveillance visit. Ipsilateral recurrence in the ureteral stump (if not fully excised) is detected at the cystoscopy visits — complete ureteral excision including bladder cuff at the time of nephroureterectomy prevents this complication.
KIMS Secunderabad — Dr. Likhiteswer Pallagani (Vattikuti Foundation uro-oncology fellowship, 400+ robotic cases, 3 peer-reviewed publications), Da Vinci Xi (four-arm — the key advantage for robotic nephroureterectomy), multidisciplinary tumour board review for every UTUC case, ureteroscopic biopsy, CT urogram, neoadjuvant and adjuvant chemotherapy coordination. Lifelong surveillance cystoscopy programme. NABH and NABL accredited. Call 040-4488-5000.